Vimarsana
Biggest News Aggregation in the World

Page 3 - Major Amendment News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Major Amendment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Major Amendment Today - Breaking & Trending Today

BioMarin Announces Incremental Progress on Biologics License Application (BLA) Review for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A Program - Vimarsana News

BioMarin Announces Incremental Progress on Biologics License Application (BLA) Review for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A Program

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today a progress update on its Biologics License Application (BLA) for valoctocogene...

Biogen Inc.: Biogen Announces FDA's 3-Month Extension of Review Period for the New Drug Application for Tofersen - Vimarsana News

Biogen Inc.: Biogen Announces FDA's 3-Month Extension of Review Period for the New Drug Application for Tofersen

The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is April 25, 2023 CAMBRIDGE, Mass., Oct. 17, 2022Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration

Oct. 4 Salida City Council, Planning Work Session Considers Salida Crossings, PROST Appointments, Budget Updates - by Ark Valley Voice Staff - Vimarsana News

Oct. 4 Salida City Council, Planning Work Session Considers Salida Crossings, PROST Appointments, Budget Updates - by Ark Valley Voice Staff

As previously reported by Ark Valley Voice, the Salida City Council work session (normally scheduled for Mon. Oct. 3) moves to 5:00 p.m. Tues. Oct. 4 at

Provention Bio Announces Extension of FDA User Fee Goal Date for Teplizumab to November 17, 2022 - Vimarsana News

Provention Bio Announces Extension of FDA User Fee Goal Date for Teplizumab to November 17, 2022

/PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated...

Regeneron Reports First Quarter 2022 Financial and Operating Results - Vimarsana News

Regeneron Reports First Quarter 2022 Financial and Operating Results

TARRYTOWN, N.Y., May 4, 2022 /PRNewswire/ --First quarter 2022 revenues increased 17% to $2.97 billion versus first quarter 2021; excluding REGEN-...